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Résumé en
anglais
The beta subunit of human chorionic gonadotropin (hCG beta) is markedly
overexpressed by neoplastic cells of differing histological origin including those
present in colon, breast, prostate and bladder tumors. We have previously shown
that some patients with hCG beta-producing urothelial tumors have circulating T
cells that proliferate in response to hCG beta. To make a comprehensive study of
hCG beta as a potential target for cancer immunotherapy, we investigated whether
hCG beta peptides could induce CD4+ or CD8+ T-cell responses in vitro. By
stimulating peripheral blood mononuclear cells (PBMCs) from three donors with
mixtures of overlapping 16-mer synthetic peptides analogous to portions of either
the hCG beta 20-71 or the hCG beta 102-129 region, we established six CD4+ T-cell
lines that proliferated specifically in response to five distinct determinants located
within these two hCG beta regions. Three antigenic determinants (hCG beta 52-67,
106-121 and 114-125) were presented by HLA-DR molecules, while the two other
antigenic determinants (hCG beta 48-63 and 56-67) were presented by HLA-DQ
molecules. Interestingly, one T-cell line specific for peptide hCG beta 106-121
recognized hCG beta peptides comprising, at position 117, either an alanine or an
aspartic acid residue, with the latter residue being present within the protein
expressed by some tumor cells. In addition, three other hCG beta-derived peptides
that exhibited HLA-A*0201 binding ability were able to stimulate CD8+ cytotoxic T
cells from two HLA-A*0201 donors. These three immunogenic peptides corresponded
to regions hCG beta 40-48, hCG beta 44-52 and hCG beta 75-84. Our results indicate
that the tumor-associated antigen hCG beta possesses numerous antigenic
determinants liable to stimulate CD4+ and CD8+ T lymphocytes, and might thus be
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